These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31778838)

  • 21. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
    Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
    [No Abstract]   [Full Text] [Related]  

  • 22. Primary Central Nervous System Lymphomas of the Brain: A Retrospective Analysis in a Single Institution.
    Lin TK; Yeh TH; Hsu PW; Chuang CC; Tu PH; Chen PY; Jung SM; Wei KC; Huang YC
    World Neurosurg; 2017 Jul; 103():550-556. PubMed ID: 28363832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.
    Song Y; Zhang W; Zhang L; Wu W; Zhang Y; Han X; Yang C; Zhang L; Zhou D
    Sci Rep; 2016 Dec; 6():38671. PubMed ID: 27924864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Cleveland Clinic experience with primary central nervous system lymphoma.
    Xie H; Ahluwalia MS; Peereboom DM
    Am J Clin Oncol; 2015 Apr; 38(2):140-6. PubMed ID: 23608829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
    Kreher S; Jöhrens K; Strehlow F; Martus P; Borowiec K; Radke J; Heppner F; Roth P; Thiel E; Pietsch T; Weller M; Korfel A
    Neuro Oncol; 2015 Jul; 17(7):1016-21. PubMed ID: 25817328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?
    Kim JA; Kim SJ; Do IG; Jin J; Nam DH; Ko YH; Kim K; Kim WS
    Leuk Lymphoma; 2011 Feb; 52(2):205-13. PubMed ID: 21281236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
    Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
    Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
    Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
    J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.
    Alame M; Cornillot E; Cacheux V; Rigau V; Costes-Martineau V; Lacheretz-Szablewski V; Colinge J
    Theranostics; 2021; 11(8):3565-3579. PubMed ID: 33664848
    [No Abstract]   [Full Text] [Related]  

  • 30. Promoter methylation attenuates SHP1 expression and function in patients with primary central nervous system lymphoma.
    Liu J; Wang Y; Sun X; Ji N; Sun S; Wang Y; Liu F; Cui Q; Wang C; Liu Y
    Oncol Rep; 2017 Feb; 37(2):887-894. PubMed ID: 27959415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.
    Hatzl S; Posch F; Deutsch A; Beham-Schmid C; Stöger H; Greinix H; Pichler M; Neumeister P; Prochazka KT
    Hematol Oncol; 2020 Aug; 38(3):277-283. PubMed ID: 32101329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical and prognostic analysis of 30 cases of primary central nervous system lymphoma].
    She C; Tan L; Li P; Ma L; Li W
    Zhonghua Xue Ye Xue Za Zhi; 2015 Apr; 36(4):282-5. PubMed ID: 25916286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
    Qian L; Zhou C; Shen J; Cen J; Yin W
    Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
    Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
    Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
    Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
    Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
    Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.
    Hatzoglou V; Oh JH; Buck O; Lin X; Lee M; Shukla-Dave A; Young RJ; Peck KK; Vachha B; Holodny AI; Grommes C
    J Neurooncol; 2018 Nov; 140(2):351-358. PubMed ID: 30073640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pemetrexed for primary central nervous system lymphoma in the elderly.
    Han S; Wang M; Liu B; Yu J
    Clin Transl Oncol; 2016 Feb; 18(2):138-43. PubMed ID: 26169215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.